Previous 10 | Next 10 |
Stanley Druckenmiller’s 13F portfolio value decreased from $3.08B to $2.76B this quarter. Duquesne increased Coupang, Carvana, Kbr, Flex, Procept Bio, and Smartsheet while decreasing Alphabet, Amazon.com, Palo Alto Networks, Starbucks, and Expedia Group. They also dropped Meta ...
Recursion Publishes First Environmental, Social and Governance (ESG) Report PR Newswire Releases inaugural report less than one year after becoming a publicly-traded company, demonstrating its strong commitment to ESG stewardship Announces new long-term commitments...
Recursion Pharmaceuticals press release (NASDAQ:RXRX): Q4 GAAP EPS of -$0.38. Revenue of $2.53M (-5.9% Y/Y). Shares +1.68% PM. For further details see: Recursion Pharmaceuticals GAAP EPS of -$0.38, revenue of $2.53M
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results PR Newswire Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointest...
Recursion (NASDAQ:RXRX) enrolled the first patient in a phase 2 trial evaluating its drug REC-994 to treat a type of neurovascular disorder called cerebral cavernous malformation (CCM) The mid-stage trial, called SYCAMORE, is a placebo-controlled study to evaluate the safety an...
Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation PR Newswire Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored clinical trial for cerebral cavernous...
The shares of the clinical-stage biotechnology company Recursion Pharmaceuticals (RXRX -10.2%) are set to close at an all-time low on Thursday after the company announced a delay for its Phase 2 trial for REC-3599 in rare genetic disorder, infantile GM2 gangliosidosis (GM). Recursion's leader...
Recursion Provides Updated Guidance on Clinical Trial Starts PR Newswire SALT LAKE CITY , March 3, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX) today provided updated guidance on clinical trial starts: Recursion's leadership team ha...
Recursion to Participate in Upcoming Investor Conferences PR Newswire SALT LAKE CITY , Feb. 8, 2022 /PRNewswire/ -- Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its ...
Recursion Pharma is hoping to revolutionize drug discovery with its Recursion OS technology; potential to improve drug discovery and processing capabilities. Recent deal with Roche brought in an upfront payment of $150 million, with potential to earn up to $300 million for each of the...
News, Short Squeeze, Breakout and More Instantly...
Recursion Pharmaceuticals Inc. Company Name:
RXRX Stock Symbol:
NASDAQ Market:
Recursion Pharmaceuticals Inc. Website:
2024-07-27 05:41:00 ET Investors looking for stocks that can make dramatic gains often turn toward the biotechnology sector. It isn't unusual for stocks in this industry to shoot higher in response to positive clinical-trial results for experimental new drugs. Recursion Pharmaceutical...
2024-07-13 09:29:00 ET Recursion Pharmaceuticals (NASDAQ: RXRX) is arguably one of the most unique drugmakers on the planet. Though it's classified as a biotech company, its claim to fame is an artificial intelligence (AI)-based approach to speeding up drug discovery and development...
2024-07-11 10:10:00 ET July 11, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at transformative innovation in biopharma, featuring Citius Pharmaceuticals, Inc. ( Nasdaq:CTXR ), a late-stage biopharmac...